Vancouver, British Columbia – (October 2nd, 2017)– BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX)
(FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed four distinguished experts
to its scientific and medical advisory team. Announcements related to each adviser will be made
through appropriate news release.

Over the past few months our new advisors have provided BioMark with excellent counsel on how to
fine tune our clinical trial protocol(s) and opened new opportunities for global collaboration. As
advisors, they will participate in scientific planning, research design, presenting to key medical opinion
leaders and evaluate our commercial strategy to successfully introduce our technology to the market.
An incentive plan was approved by Board of Directors that consisted of aggregated 420,000 shares
valued at 10 cents for services offered in 2017 fiscal year plus aggregated 350,000 options exercisable
at 15 cents under BioMark’s option plan and will vest over 3 years plus a negotiable travel allowance.

Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome our new
scientific and medical advisors to our company. Their demonstrated ability to lead, offer clinical design
wisdom and connect emerging technologies would be a tremendous boost to BioMark. This is what
BioMark needs as we transition into a successful commercial entity.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can
help detect, monitor and assess treatment for cancer early and cost effectively. The technology can
also be used for measuring response to treatment and potentially for serial monitoring for cancer

Further information about BioMark is available under its profile on the SEDAR website
and on the CSE website

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities
legislation, concerning the business of BioMark. Forward-looking information is based on certain key
expectations and assumptions made by the management of BioMark. Although BioMark believes that
the expectations and assumptions on which such forward-looking information is based are reasonable,
undue reliance should not be placed on the forward-looking information because BioMark can give no
assurance that they will prove to be correct. Forward-looking statements contained in this press
release are made as of the date of this press release. BioMark disclaims any intent or obligation to
update publicly any forward-looking information, whether as a result of new information, future
events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release



Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.